EUCTR2015-002649-69-DE进行中（未招募）1 期
A 24-Week Multicenter, Randomized, Open-Label, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients with Moderate-to-Severe Plaque Psoriasis who are Naive to Systemic Treatment
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 162
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1]Present with moderate-to-severe chronic plaque psoriasis based on a diagnosis of chronic psoriasis for at least 6 months before baseline (Week 0; Visit 2), as determined by the investigator
- •[2]Patients who are candidates for systemic therapy, and who are naive to systemic treatment for psoriasis.
- •[3]Have a PASI score =10 and BSA =10 at screening (Visit 1) and at baseline (Week 0, Visit 2)
- •[4]Are male or female patients of 18 years or older
- •[5]If a male patient, agree to use a reliable method of birth control during the study and for at least 6 month following the last dose of investigational product. Male patients should not donate sperm during this period.
- •[6]If a female patient of childbearing potential, must test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study and for at least 15 weeks following the last dose of investigational product. Methods of contraception considered acceptable include oral contraceptives, contraceptive patch, intrauterine device, vaginal ring, diaphragm with contraceptive gel, or condom with contraceptive gel
- •[7]For non-childbearing potential female patients, patients must be:
- •women who have had surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation),
- •women who are =60 years of age,
- •women =40 and <60 years of age who have had a cessation of menses for =12 months and a follicle-stimulating hormone (FSH) test confirming non–childbearing potential (=40 mIU/mL)
- •[8]Have a chest x-ray or results from chest x-ray obtained within 6 months before screening visit
- •[9]Have given written informed consent approved by Lilly, or its designee, and the Institutional Review Board (IRB)/ERB governing the site
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •10 Have predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis
- •11 Have a history of drug-induced psoriasis
- •12 Have received systemic nonbiologic psoriasis therapy
- •13 Have received natalizumab, or other agents targeting a 4 integrin
- •14 Have received phototherapy within 4 weeks of baseline or have had topical psoriasis treatment within 2 weeks of baseline
- •15 Exceptions: low potency to mild potency topical steroids will be permitted for use limited to the face, axilla, groin and/or genitalia Have prior, concurrent, or recent use of ixekizumab or any other biological psoriasis therapy
- •16 Have any condition or contraindication as addressed in the local labeling for methotrexate or FAE that would preclude the patient from participating
- •18 Have had a live vaccination within 12 weeks of baseline, or intend to have a live vaccination during the course of the study or within 15 weeks of completing treatment in this study, or have participated in a vaccine clinical study within 12 weeks of baseline
- •19 Have had a vaccination with BCG within 12 months of baseline or intend to have vaccination with BCG during the course of the study or within 12 months of completing treatment in this study
- •20 Have a known allergy or hypersensitivity to any biologic therapy that would pose an unacceptable risk to the patient
- •22 Have had any major surgery within 8 weeks of baseline or will require surgery during the study that would pose an unacceptable risk
- •23 Have active or history of malignant disease within 5 years prior to baseline
- •24 Presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic, or neuropsychiatric disorders or abnormal laboratory values at screening that pose an unacceptable risk to the patient or of interfering with the interpretation of data
- •25 Have ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the patient
- •26 Presence of significant uncontrolled neuropsychiatric disorder, have history of a suicide attempt, have a score of 3 on Item 12 (Thoughts of Death or Suicide) of the QIDS-SR16 at screening or baseline or are clinically judged by the investigator to be at risk for suicide
- •27 Have evidence or suspicion of active or latent TB
- •28 Have a known immunodeficiency
- •29 Are positive for human immunodeficiency virus serology
- •30 Have evidence of or test positive for HBV by testing positive for anti-hepatitis B core antibody and HBV DNA positive
- •31 Have evidence of or test positive for hepatitis C virus.
- •32 Have a body temperature =38°C at baseline, these patients may be re screened (1 time) =4 weeks after documented resolution of elevated temperature.
- •34 Have severe gastrointestinal disease, oral ulcer, or known, active gastrointestinal ulcer
- •35 Are women who are planning to become pregnant, who are pregnant, or who are breast feeding
- •36 Have had a serious infection, have been hospitalized, or have received intravenous antibiotics for an infection within 12 weeks of baseline; have had a serious bone or joint infection within 24 weeks of baseline, or have ever had an infection of an artificial joint; or are immunocompromised to an extent such that participation in the study would pose an unacceptable risk
- •37 Have or have had an infection typical of an immunocompromised host and/or that occurs with increased incidence in an immunocompromised host
研究者
相似试验
进行中（未招募）
1 期
Gla-300 and IDeg-100 in Insulin-Naïve People with Type 2 Diabetes Mellitus and Renal ImpairmentEUCTR2022-001485-35-HUSanofi-Aventis Recherche & Développement630
进行中（未招募）
1 期
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficiency (GHD)EUCTR2020-000874-92-PLumos Pharma, Inc.80
进行中（未招募）
1 期
Comparison of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus patientsType 2 diabetes mellitusMedDRA version: 19.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-001626-42-CZsanofi-aventis recherche & développement592
进行中（未招募）
1 期
Comparison of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus patientsEUCTR2015-001626-42-HRsanofi-aventis recherche & développement592
进行中（未招募）
1 期
Comparison of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus patientsEUCTR2015-001626-42-SKsanofi-aventis Groupe592